CN106866784A - Targetted mitochondria antioxidant and its production and use - Google Patents
Targetted mitochondria antioxidant and its production and use Download PDFInfo
- Publication number
- CN106866784A CN106866784A CN201611130474.3A CN201611130474A CN106866784A CN 106866784 A CN106866784 A CN 106866784A CN 201611130474 A CN201611130474 A CN 201611130474A CN 106866784 A CN106866784 A CN 106866784A
- Authority
- CN
- China
- Prior art keywords
- tert
- compound
- methyl
- benzyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 230000003078 antioxidant effect Effects 0.000 title description 5
- 239000003963 antioxidant agent Substances 0.000 title description 4
- 210000003470 mitochondria Anatomy 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 125
- -1 hydrate Substances 0.000 claims abstract description 51
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims abstract description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 8
- 239000002207 metabolite Substances 0.000 claims abstract description 7
- 239000012453 solvate Substances 0.000 claims abstract description 6
- 208000035719 Maculopathy Diseases 0.000 claims abstract description 4
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- OJOFMLDBXPDXLQ-VIFPVBQESA-N (4s)-4-benzyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@H]1CC1=CC=CC=C1 OJOFMLDBXPDXLQ-VIFPVBQESA-N 0.000 claims description 10
- 208000023105 Huntington disease Diseases 0.000 claims description 10
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- 230000009529 traumatic brain injury Effects 0.000 claims description 9
- YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 208000010412 Glaucoma Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- XEVOHWHMATVWAF-LLSOJIOMSA-N (e,2s,5s)-2-benzyl-7-methyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]oct-3-enoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CC(C)C)\C=C\[C@@H](C(O)=O)CC1=CC=CC=C1 XEVOHWHMATVWAF-LLSOJIOMSA-N 0.000 claims description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 5
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 claims description 5
- KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 claims description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 150000001718 carbodiimides Chemical class 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N 1-butanol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 3
- AYSOUYKQIUYGFR-UHFFFAOYSA-N 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-amine Chemical compound CC1(C)CC(N)CC(C)(C)N1O AYSOUYKQIUYGFR-UHFFFAOYSA-N 0.000 claims description 3
- 239000003810 Jones reagent Substances 0.000 claims description 3
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 claims description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 claims description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 claims description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- NJTCEXRGYVYYIX-SLFFLAALSA-N methyl (2S)-2-[[(2R)-3-methyl-2-[[(2S)-pyrrolidine-2-carbonyl]amino]butanoyl]amino]-5-(phenylmethoxycarbonylamino)pentanoate Chemical compound C(C1=CC=CC=C1)OC(=O)NCCC[C@@H](C(=O)OC)NC([C@@H](C(C)C)NC(=O)[C@H]1NCCC1)=O NJTCEXRGYVYYIX-SLFFLAALSA-N 0.000 claims description 3
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 3
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 230000002438 mitochondrial effect Effects 0.000 abstract description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 6
- 230000004792 oxidative damage Effects 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract description 3
- 210000005036 nerve Anatomy 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 24
- 239000004480 active ingredient Substances 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- VDQKIDYOPUMJGQ-VQPCLXHQSA-N XJB-5-131 Chemical compound C([C@@H](/C=C/[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=O)OCC=1C=CC=CC=1)C(=O)NC1CC(C)(C)N([O])C(C)(C)C1)C1=CC=CC=C1 VDQKIDYOPUMJGQ-VQPCLXHQSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 150000001204 N-oxides Chemical class 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 208000011325 dry age related macular degeneration Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 229940125758 compound 15 Drugs 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
- 229940126657 Compound 17 Drugs 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229940125797 compound 12 Drugs 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 229940125810 compound 20 Drugs 0.000 description 4
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- 241000220479 Acacia Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- BKQFRNYHFIQEKN-UHFFFAOYSA-N erastin Chemical compound CCOC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C(C)N1CCN(C(=O)COC=2C=CC(Cl)=CC=2)CC1 BKQFRNYHFIQEKN-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 0 CC(C)[C@](C(N[C@@](CCC*)C(NC(CC1(C)C)=CC(C)(C)N1O)=O)=O)NC([C@](CCC1)N1C(CC=CC(C1)(C1C(C)C)NC(OC(C)(C)C)=O)=O)=O Chemical compound CC(C)[C@](C(N[C@@](CCC*)C(NC(CC1(C)C)=CC(C)(C)N1O)=O)=O)NC([C@](CCC1)N1C(CC=CC(C1)(C1C(C)C)NC(OC(C)(C)C)=O)=O)=O 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004806 ferroptosis Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000004701 malic acid derivatives Chemical class 0.000 description 2
- 150000002690 malonic acid derivatives Chemical class 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 230000005311 nuclear magnetism Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- NCGCHLRUCHBDES-WDEREUQCSA-N (2r)-3-methyl-2-[[(2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carbonyl]amino]butanoic acid Chemical compound CC(C)[C@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)OC(C)(C)C NCGCHLRUCHBDES-WDEREUQCSA-N 0.000 description 1
- VULSXQYFUHKBAN-NSHDSACASA-N (2s)-2-azaniumyl-5-(phenylmethoxycarbonylamino)pentanoate Chemical compound OC(=O)[C@@H](N)CCCNC(=O)OCC1=CC=CC=C1 VULSXQYFUHKBAN-NSHDSACASA-N 0.000 description 1
- HOFUGGFJBSCHEW-UHFFFAOYSA-N (4-prop-2-enoxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(OCC=C)C=C1 HOFUGGFJBSCHEW-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- KMHZPJNVPCAUMN-UHFFFAOYSA-N Erbon Chemical compound CC(Cl)(Cl)C(=O)OCCOC1=CC(Cl)=C(Cl)C=C1Cl KMHZPJNVPCAUMN-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000510 ammonia Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- OTJZCIYGRUNXTP-UHFFFAOYSA-N but-3-yn-1-ol Chemical compound OCCC#C OTJZCIYGRUNXTP-UHFFFAOYSA-N 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- MRKZAZMYXYSBDG-UHFFFAOYSA-N cyclopentyl propanoate Chemical class CCC(=O)OC1CCCC1 MRKZAZMYXYSBDG-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000027993 eye symptom Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 125000005612 glucoheptonate group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002189 macula lutea Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- ZUJMKNWYEVTCNT-YDALLXLXSA-N methyl (2s)-2-amino-5-(phenylmethoxycarbonylamino)pentanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CCCNC(=O)OCC1=CC=CC=C1 ZUJMKNWYEVTCNT-YDALLXLXSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- GODHIFXMNKQHEI-UHFFFAOYSA-N pentanoic acid;hydrochloride Chemical compound Cl.CCCCC(O)=O GODHIFXMNKQHEI-UHFFFAOYSA-N 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical group OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- LFILDSDQMSCNBV-LURJTMIESA-N propane-2-sulfinamide Chemical compound CC(C)[S@@](N)=O LFILDSDQMSCNBV-LURJTMIESA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical class [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- VTORJPDWMOIOIQ-UHFFFAOYSA-N tert-butyl(diphenyl)silane Chemical compound C=1C=CC=CC=1[SiH](C(C)(C)C)C1=CC=CC=C1 VTORJPDWMOIOIQ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of compound, it is the stereoisomer of compound, geometric isomer, dynamic isomer, nitrogen oxides, hydrate, solvate, metabolite, pharmaceutically acceptable salt shown in the compound that Formulas I is shown or Formulas I, wherein, Cbz represents benzyloxycarbonyl group, Bn represents benzyl, and Boc represents tertbutyloxycarbonyl.The compound stable in physicochemical property, and the water-soluble raising compared with XJB 5 131, physicochemical properties stabilization, and bioactivity is good, pharmaceutical dosage is small, internal stability is improved, bioavilability is high, Small side effects, and targeting inoxidizability is protruded, can be effective for repairing Mitochondrial oxidative damage, the nerve degenerative diseases such as prevention or treatment treating senile maculopathy.
Description
PRIORITY INFORMATION
This application claims priority and benefit to patent application No. 201510922167.8 filed on 11/12/2015 with the chinese national intellectual property office, and is incorporated herein by reference in its entirety.
Technical Field
The invention relates to the technical field of biochemistry, in particular to the field of compound preparation, and more particularly relates to a novel compound (formula I) and a preparation method and application thereof.
Background
Mitochondrial oxidative damage is associated with a number of neurodegenerative diseases including Dry senile maculopathy (Dry-AMD), Glaucoma (Glaucoma), Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease (AD), Parkinson's Disease (PD), Huntington's Disease (HD), and the like. Among them, Huntington's chorea is a genetic disease in which neurons in some regions of the brain are increasingly weakened. Disease symptoms, including loss of muscle coordination and decline in cognitive abilities, often manifest in middle age. The disease cannot be cured at present. Currently, physicians only administer patients with antidepressants or compounds that reduce the loss of motor coordination, both of which fail to slow the progression of the disease.
XJB-5-131 is a mitochondrial antioxidant with good targeting property, has good biological activity, and has been studied to show that XJB-5-131 has obvious curative effect in animal models of neurodegeneration of traumatic brain injury and animal models of Huntington's disease, and has good clinical application prospect (for example, see Nature Neuroscience2012,15(10), 1407; Accounts of Chemical Research 2008,41(1), 87; J.Am.chem.Soc.2005,127,12460, which is incorporated herein by reference in its entirety).
Disclosure of Invention
The present invention is directed to solving at least one of the problems of the prior art. Therefore, an object of the present invention is to provide a compound with stable physicochemical properties and better potential bioactivity and mitochondrial antioxidant property compared with XJB-5-131.
It should be noted that the present invention is completed based on the following work of the inventors: a plurality of analogues are obtained by carrying out structural optimization on XJB-5-131, and then a series of biological researches and animal model tests are carried out on the various analogues so as to screen out a novel mitochondrial antioxidant with good biological activity, outstanding targeted oxidation resistance and stable physicochemical property. As a result, the compound (namely the compound shown in the formula I) obtained by screening is stable in physicochemical property, higher in water solubility, more stable in crystal form, good in biological activity, small in medicinal dosage, high in-vivo bioavailability, small in side effect and prominent in targeted oxidation resistance compared with XJB-5-131. Furthermore, animal model experiments show that the compound I can effectively repair the injury of eye macula lutea of SD rats, prevent the apoptosis of retina layer cells of the rats and protect the retina cells, thereby relieving the eye symptoms of the rats.
Thus, according to one aspect of the invention, there is provided a compound. According to an embodiment of the invention, the compound is a compound of formula I or a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt of a compound of formula I,
wherein,
cbz represents benzyloxycarbonyl, Bn represents benzyl, and Boc represents t-butoxycarbonyl.
The inventor finds that the compound has stable physicochemical properties, higher water solubility than XJB-5-131, easy crystallization, stable physicochemical properties, good biological activity, small medicinal dosage, high in-vivo bioavailability, small side effect and outstanding targeted antioxidation performance, can be effectively used for repairing mitochondrial oxidative damage and preventing or treating neurodegenerative diseases such as Dry senile maculopathy (Dry-AMD), Glaucoma (Glaucoma), Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease (AD), Parkinson Disease (PD), Huntington's Disease (HD) and the like.
It is to be noted that, unless otherwise indicated, all tautomeric forms of the compounds of the invention are included within the scope of the invention. In addition, unless otherwise indicated, the structural formulae of the compounds described herein include isotopically enriched concentrations of one or more different atoms.
The term "hydrate" as used herein refers to a compound provided by the present invention or a salt thereof, which further comprises water bound by non-covalent intermolecular forces in a chemical amount or in a non-chemical equivalent amount, and may be said to be an association of solvent molecules with water.
The term "solvate" refers to an association of one or more solvent molecules with a compound of the invention. Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, aminoethanol.
The term "nitroxide" means that when a compound contains several amine functional groups, 1 or more than 1 nitrogen atom can be oxidized to form an N-oxide. Specific examples of N-oxides are N-oxides of tertiary amines or N-oxides of nitrogen-containing heterocyclic nitrogen atoms. The corresponding amines can be treated with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid) to form the N-oxide (see Advanced Organic Chemistry, Wiley Interscience, 4 th edition, Jerry March). In particular, the N-oxide may be prepared by the method of L.W.Deady (Syn.Comm.1977,7,509-514) in which an amine compound is reacted with m-chloroperoxybenzoic acid (mCPBA), for example, in an inert solvent such as methylene chloride.
The term "metabolite" refers to the product of the metabolism of a particular compound or salt thereof in vivo. Metabolites of a compound can be identified by techniques well known in the art, and its activity can be characterized by assay methods as described herein. Such products may be obtained by administering the compound by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, defatting, enzymatic cleavage, and the like. Accordingly, the present invention includes metabolites of compounds, including metabolites produced by contacting a compound of the present invention with a mammal for a sufficient period of time.
Various pharmaceutically acceptable salt forms of the compounds of the present invention are useful. The term "pharmaceutically acceptable salts" means those salt forms that are readily apparent to the pharmaceutical chemist as being substantially non-toxic and providing the desired pharmacokinetic properties, palatability, absorption, distribution, metabolism or excretion. Other factors, more practical in nature, are also important for selection, these are: cost of raw materials, ease of crystallization, yield, stability, hygroscopicity and, as a result, flowability of the drug substance. Briefly, the pharmaceutical composition can be prepared by combining the active ingredient with a pharmaceutically acceptable carrier.
The term "pharmaceutically acceptable salts" as used herein refers to both organic and inorganic salts of the compounds of the present invention. Pharmaceutically acceptable salts are well known in the art, as are: berge et al, description of the descriptive pharmaceutical acceptable salts in detail in J. pharmaceutical sciences,66:1-19,1977. Pharmaceutically acceptable non-toxic acid salts include, but are not limited to, salts of inorganic acids formed by reaction with amino groups such as hydrochlorides, hydrobromides, phosphates, sulfates, perchlorates, and salts of organic acids such as acetates, oxalates, maleates, tartrates, citrates, succinates, malonates, or those obtained by other methods described in the literature above, such as ion exchange. It is composed ofPharmaceutically acceptable salts thereof include adipates, malates, 2-hydroxypropionates, alginates, ascorbates, aspartates, benzenesulfonates, benzoates, bisulfates, borates, butyrates, camphorates, camphorsulfonates, cyclopentylpropionates, digluconates, dodecylsulfates, ethanesulfonates, formates, fumarates, glucoheptonates, glycerophosphates, gluconates, hemisulfates, heptanoates, caproates, hydroiodiates, 2-hydroxy-ethanesulfonates, lactobionates, lactates, laurylsulfates, malates, malonates, methanesulfonates, 2-naphthalenesulfonates, nicotinates, nitrates, oleates, palmitates, embonate, pectinates, persulfates, 3-phenylpropionates, picrates, pivalate, propionate, stearate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Salts obtained with appropriate bases include alkali metals, alkaline earth metals, ammonium and N+(C1-4Alkyl radical)4A salt. The present invention also contemplates quaternary ammonium salts formed from compounds containing groups of N. Water-soluble or oil-soluble or dispersion products can be obtained by quaternization. Alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Pharmaceutically acceptable salts further include suitable, non-toxic ammonium, quaternary ammonium salts and amine cations resistant to formation of counterions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, C1-8Sulfonates and aromatic sulfonates. Amine salts such as, but not limited to, N '-dibenzylethylenediamine, chloroprocaine, choline, ammonia, isopropylamine, benzathine (benzathine), choline (cholinate), lysine, meglumine (meglumine), piperazine, tromethamine, diethanolamine and other hydroxyalkylamine salts, ethylenediamine, N-methyl reduced glucamine, procaine, N-benzylphenethylamine, 1-p-chlorobenzyl-2-pyrrolidin-1' -ylmethyl-benzimidazolium and other alkylamine salts, piperazine and tris (hydroxymethyl) aminomethane; alkaline earth metal salts such as, but not limited to, barium, calcium and magnesium salts; a transition metal salt of a metal selected from the group consisting of,such as but not limited to zinc salts.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound, basic or acidic moiety, by conventional chemical methods. In general, such salts can be prepared by reacting the free acid forms of these compounds with a stoichiometric amount of the appropriate base (e.g., Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, etc.), or by reacting the free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are usually carried out in water or an organic solvent or a mixture of both. Generally, where appropriate, it is desirable to use a non-aqueous medium such as diethyl ether, ethyl acetate, ethanol, isopropanol or acetonitrile. In, for example, "Remington's Pharmaceutical Sciences", 20 th edition, Mack publishing company, Easton, Pa., (1985); and "handbook of pharmaceutically acceptable salts: properties, Selection and application (Handbook of pharmaceutical Salts: Properties, Selection, and Use) ", Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002) may find some additional lists of suitable Salts.
In addition, the compounds disclosed herein, including their salts, may also be obtained in the form of their hydrates or in the form of solvents containing them (e.g., ethanol, DMSO, etc.), for their crystallization. The compounds disclosed herein may form solvates with pharmaceutically acceptable solvents (including water), either inherently or by design; thus, the present invention is intended to include both solvated and unsolvated forms.
The term "treating" or "treatment" as used herein refers, in some embodiments, to ameliorating a disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one clinical symptom thereof). In other embodiments, "treating" refers to moderating or improving at least one physical parameter, including physical parameters that may not be perceived by the patient. In other embodiments, "treating" or "treatment" refers to modulating the disease or disorder, either physically (e.g., stabilizing a perceptible symptom) or physiologically (e.g., stabilizing a parameter of the body), or both. In other embodiments, "treating" or "treatment" refers to preventing or delaying the onset, occurrence, or worsening of a disease or disorder.
According to a further aspect of the invention there is provided a method for preparing a compound as hereinbefore described. According to an embodiment of the invention, the method comprises the steps of:
contacting 3-yne-1-butanol with imidazole and tert-butyldiphenylchlorosilane so as to obtain (3-yne-1-butyloxy) tert-butyldiphenylsilyl ether;
contacting 3-methylbutanal with (R) -tert-butylsulfenamide, magnesium sulfate and PPTS, so as to obtain (R) - ((E) -isoamylimine) -tert-butylsulfenamide;
contacting (3-yne-1-butyloxy) tert-butyldiphenylsilyl ether with (R) - ((E) -isoamylimine) -tert-butylsulfinamide, so as to obtain 8-tert-butyldiphenylsiloxy-2-methyl-5-octene- (S) -4-aza- (R) -tert-butylsulfinamide;
contacting 8-tert-butyldiphenylsiloxy-2-methyl-5-octene- (S) -4-aza- (R) -tert-butylsulfinamide with a solid sodium bicarbonate to obtain (S, E) -tert-butyl- (8-hydroxy-2-methyl-5-octene) carbamate;
contacting (S, E) -tert-butyl- (8-hydroxy-2-methyl-5-octene) carbamate with jones reagent to obtain (S, E) -5- ((tert-butylcarbonyl) amino) -7-methyl-3 octenoic acid;
contacting (S, E) -5- ((tert-butylcarbonyl) amino) -7-methyl-3 octenoic acid with (S) -4-benzyl-3-oxazolidinone to obtain tert-butyl ((S, E) -8- ((S) -4-benzyl-2-oxazolidinone) -2-methyl-8-carbonyl-5-enyl) -carbamate;
contacting tert-butyl ((S, E) -8- ((S) -4-benzyl-2-oxazolidinone) -2-methyl-8-carbonyl-5-enyl) -carbamate with tetrahydrofuran and benzyl bromide to obtain tert-butyl ((4S,7S, E) -7-benzyl-8- ((S) -4-benzyl-oxazolidinone) -2-methyl-8-carbonyl-5-enyl) -carbamate;
contacting tert-butyl ((4S,7S, E) -7-benzyl-8- ((S) -4-benzyl-oxazolidinone) -2-methyl-8-carbonyl-5-enyl) -carbamate with hydrogen peroxide, lithium hydroxide monohydrate, and sodium thiosulfate to obtain (2S,5S, E) -2-benzyl-5- ((tert-butoxycarbonyl) amino) -7-methyl-3-octenoic acid;
contacting (2S,5S, E) -2-benzyl-5- ((tert-butoxycarbonyl) amino) -7-methyl-3-octenoic acid with (S) -5- ((benzyloxycarbonyl) amino) -2- ((R) -3-methyl-2 ((S) -pyrrolidine-2-carboxamido) -butyrylamino) pentanoic acid methyl ester, so as to obtain (S) -methyl 2- ((R) -2- ((S) -1- (2S,5S, E) -2-benzyl-5- ((tert-butoxycarbonyl) amino) -7-methyl-3-octene) pyrrolidinyl-2-carboxamido) -3-methylbutanamido) -5- ((benzyloxycarbonyl) amino) pentanoate; and
contacting methyl (S) -2- ((R) -2- ((S) -1- (2S,5S, E) -2-benzyl-5- ((tert-butoxycarbonyl) amino) -7-methyl-3-octene) pyrrolidinyl-2-carboxamido) -3-methylbutanamido) -5- ((benzyloxycarbonyl) amino) pentanoate with sodium hydroxide to give a crude product, and then contacting the crude product with 4-amino 2,2,6, 6-tetramethylpiperidine oxide, 1-hydroxybenzotriazole, carbodiimide, and 4-dimethylaminopyridine to obtain the compound described previously.
Therefore, the method can be used for efficiently preparing the compound shown in the formula I, and has the advantages of few steps, low cost, good stability of the obtained compound, and outstanding bioactivity and mitochondrion targeting oxidation resistance.
Wherein, when useful in therapy, a therapeutically effective amount of a compound of formula I and pharmaceutically acceptable salts thereof may be administered as a raw chemical or may be provided as an active ingredient in a pharmaceutical composition. Thus, according to a further aspect of the invention, there is also provided a pharmaceutical composition. According to an embodiment of the invention, the pharmaceutical composition comprises a compound as described above. The inventor finds that the pharmaceutical composition can effectively repair mitochondrial oxidative damage, and thus can be effectively used for preventing or treating neurodegenerative diseases such as Dry age-related macular degeneration (Dry-AMD), Glaucoma (Glaucoma), Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease (AD), Parkinson's Disease (PD), Huntington's Disease (HD) and the like.
According to an embodiment of the present invention, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle, or any combination thereof.
Suitable carriers, adjuvants and excipients are well known to those skilled in the art and are described in detail, for example, in Ansel h.c.et al, Ansel's Pharmaceutical Dosage Forms and Drug delivery systems (2004) Lippincott, Williams & Wilkins, philidelphia; gennaro a.r.et al, Remington: the Science and Practice of Pharmacy (2000) Lippincott, Williams & Wilkins, Philadelphia; and Rowe R.C., Handbook of Pharmaceutical Excipients (2005) Pharmaceutical Press, Chicago.
The term "therapeutically effective amount" as used herein refers to the total amount of each active ingredient sufficient to show meaningful patient benefit. When the active ingredient alone is used for separate administration, the term refers only to that ingredient. When used in combination, the term refers to the combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, sequentially or simultaneously. The compounds of formula I and their pharmaceutically acceptable salts are as described above. The carrier, diluent or excipient must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. According to another aspect of the present disclosure there is also provided a process for the preparation of a pharmaceutical formulation, which process comprises admixing a compound of formula I, or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients. The term "pharmaceutically acceptable" as used herein refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use.
In general, the compounds of the present invention are administered in therapeutically effective amounts by any conventional means of administration for substances that exert similar effects. The appropriate dosage range will depend upon a variety of factors such as the severity of the disease being treated, the age and relative health of the subject being administered, the potency of the compound used, the route and form of administration, the indication for which administration is being effected and the preferences and experience of the relevant medical practitioner. One of ordinary skill in the art of treating such diseases will be able to determine, without undue experimentation and relying on personal knowledge and the disclosure of this application, a therapeutically effective amount of a compound of the present invention for a given disease.
Typically, the compounds of the invention are administered in the form of pharmaceutical formulations including those suitable for oral (including buccal and sublingual), rectal, nasal, topical, pulmonary, vaginal or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or for administration by inhalation or insufflation. The preferred mode of administration is generally oral, and may be adjusted to the level of pain using a suitable daily dosage regimen.
One or more compounds of the present invention may be presented in pharmaceutical compositions and unit dosage forms together with one or more conventional adjuvants, carriers or diluents. The pharmaceutical compositions and unit dosage forms can contain conventional ingredients in conventional proportions, with or without additional active compounds or ingredients, and the unit dosage forms can contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions may be applied in the form of solids such as tablets or filled capsules, semisolids, powders, sustained release formulations or liquids such as solutions, suspensions, emulsions, elixirs or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of a sterile injectable solution for parenteral use.
The compounds of the present invention may be formulated in a variety of orally administered dosage forms. Pharmaceutical compositions and dosage forms may comprise one or more compounds of the invention or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutically acceptable carrier may be a solid or a liquid. Formulations in solid form include: powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is typically a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is usually mixed with a carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. Suitable carriers include, but are not limited to, magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, and the like. The term "formulation" is intended to include preparations of the active compound that contain the encapsulating material as a carrier to provide a capsule in which the active ingredient, with or without a carrier, is surrounded by the carrier in association therewith. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges are solid forms suitable for oral administration.
Other forms suitable for oral administration include liquid form preparations (including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions) or solid form preparations which are intended to be converted into a liquid form preparation immediately before use. Emulsions may be prepared in solutions such as aqueous propylene glycol or may contain emulsifying agents such as lecithin, sorbitan monooleate or acacia. Aqueous solutions can be prepared by dissolving the active ingredient in water and adding suitable colorants, flavors, stabilizers, and thickening agents. Aqueous suspensions may be formulated by dispersing the finely divided active ingredient in water with viscous material, for example, natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose and other well-known suspending agents. Liquid form preparations include solutions, suspensions, and emulsions, which may contain, in addition to the active ingredient, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The compounds of the invention may be formulated for parenteral administration (e.g., by injection, such as bolus injection or continuous infusion) and may be presented in unit dosage form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or non-aqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g. olive oil) and injectable organic esters (e.g. ethyl oleate), and may contain formulatory agents such as preservatives, wetting agents, emulsifying or suspending agents, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic packaging of a sterile solid or by lyophilisation of a solution for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
The compounds of the present invention may be formulated for topical application to the epidermis in the form of an ointment, cream or lotion, or in the form of a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. Formulations suitable for topical administration in the mouth include: lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
The compounds of the present invention may be formulated for administration in the form of suppositories. The low melting wax, such as a fatty acid glyceride mixture or cocoa butter, can be melted first and the active ingredient dispersed homogeneously, for example by stirring. The molten homogeneous mixture is then poured into a suitably sized mold, allowed to cool and solidify.
The compounds of the present invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
The compounds of the present invention may be formulated for nasal administration. The solutions or suspensions can be applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or nebulizer. The formulations may be in single or multiple dose form. For a dropper or pipette multi-dose form, this may be achieved by the patient administering an appropriate, predetermined volume of solution or suspension. For a nebulizer, this can be achieved, for example, by a metered atomizing spray pump.
The compounds of the invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration. The compounds typically have small particle sizes, for example, on the order of 5 microns or less. The particle size may be obtained by methods well known in the art, for example by micronization. The active ingredient is provided in pressurized packs containing a suitable propellant, such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas. The aerosol may also suitably contain a surfactant such as lecithin. The dosage of the medicament may be controlled by a metering valve. Alternatively, the active ingredient may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone. The powder carrier will form a gel in the nasal cavity. The powder compositions may be presented in unit dosage form, for example in gelatin capsules or cartridges or blister packs from which the powder may be administered by means of an inhaler.
If desired, the formulations may be prepared with enteric coatings suitable for sustained or controlled release administration of the active ingredient. For example, the compounds of the present invention may be formulated as transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with the treatment regimen is critical. The compounds in transdermal delivery systems are often attached to a skin-adherent solid carrier. The compounds of interest may also be used in combination with a penetration enhancer, such as laurocapram (1-dodecyl azepan-2-one). The sustained release delivery system may be inserted subcutaneously into the subcutaneous layer by surgery or injection. Subcutaneous implants encapsulate compounds in a liquid soluble film, such as silicone rubber, or a biodegradable polymer, such as polylactic acid.
The pharmaceutical preparation is preferably in unit dosage form. In this form, the preparation is subdivided into unit doses containing appropriate quantities of the active ingredient. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as tablets, capsules, and powders or ampoules in vials. In addition, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in a packaged form.
Other suitable pharmaceutical carriers and their formulations are described in Remington: the Science and Practice of pharmacy1995Martin, edited by E.W, Mack Publishing Company, 19 th edition, Easton, Pennsylvania.
According to another aspect of the present invention, there is also provided the use of a compound or pharmaceutical composition as described above in the manufacture of a medicament for the prevention or treatment of a neurodegenerative disease.
According to an embodiment of the invention, the neurodegenerative disease is dry age-related macular, glaucoma, traumatic brain injury, amyotrophic lateral sclerosis, alzheimer's disease, parkinson's disease, huntington's disease.
It is noted that the compounds and pharmaceutical compositions of the present invention, in addition to being beneficial for human therapy, may also find application in veterinary therapy for pets, animals of the introduced species, and mammals in farm animals. Examples of other animals include horses, dogs, and cats. Herein, the compound of the present invention includes pharmaceutically acceptable derivatives thereof.
Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Drawings
The above and/or additional aspects and advantages of the present invention will become apparent and readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawings of which:
FIGS. 1-2 show results of pH stability studies according to one embodiment of the present invention;
FIG. 3 shows the results of the test of the inhibitory effect of Compound I on Erastin-induced HT1080 cell iron death, according to one embodiment of the present invention;
FIG. 4 shows the results of a test for the recovery of damaged ARPE-19 cells from hydrogen peroxide by Compound I, according to an embodiment of the present invention;
FIG. 5 shows the results of visual electrophysiological examination of Compound I, according to one embodiment of the present invention.
Detailed Description
The scheme of the invention will be explained with reference to the examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the invention only and should not be taken as limiting the scope of the invention. The examples, where specific techniques or conditions are not indicated, are to be construed according to the techniques or conditions described in the literature in the art or according to the product specifications. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
EXAMPLE 1 preparation of Compound I
A,Intermediate 13 synthesis:
first, intermediate 13 was synthesized according to the following synthetic route:
the method comprises the following steps: synthesis of Compound 5
Compound 4(10g, 37.6mmol) was dissolved in methanol (150mL), cooled to 0 deg.C, and thionyl chloride (22g, 0.19mmol) was added dropwise thereto.
The reaction solution was gradually warmed to room temperature with stirring, and stirring was continued for 12 hours. The reaction mixture was concentrated under reduced pressure to give compound 5(11.7g) in 98% yield.
Step two: synthesis of Compound 2
Compound 1(6.45g, 30mmol) and D-Valine methyl ester hydrochloride (5.53g, 33mmol) were dissolved in dichloromethane (200mL) and cooled to 0 ℃. To the above solution were added 1-hydroxybenzotriazole (4.46g, 33mmol), carbodiimide (6.3g, 33mmol) and DIEA (8.51g, 66 mmol).
The reaction was gradually warmed to room temperature, stirred for 12h, quenched with aqueous hydrochloric acid (100mL, 1M), and extracted with dichloromethane (200 mL. times.3). The organic phases were combined and washed with saturated aqueous sodium chloride (100 mL). Separating, collecting organic phase, drying, and concentrating. The residue was subjected to silica gel column chromatography to give compound 2(9.1g) in 93% yield.
Step three: synthesis of Compound 3
Compound 2(2.0g, 6.1mmol) was dissolved in tetrahydrofuran/methanol/water (8mL/4mL/2mL), cooled to 0 deg.C, and a lithium hydroxide solution (10mL, 1M aqueous solution) was added dropwise thereto.
The reaction was stirred at 0 ℃ for 2 h. Most of the tetrahydrofuran was removed under reduced pressure, and the residue was acidified with aqueous hydrochloric acid (20mL,1M) and then extracted with ethyl acetate (50 mL. times.2). The organic phases were combined and washed with saturated aqueous sodium chloride (30 mL). The organic phase was collected by liquid separation, dried and concentrated to obtain compound 3(1.8g) as a white solid with a yield of 95%.
Step three: synthesis of Compound 6
Compound 3(5g, 15.9mmol) and compound 5(6g, 19mmol) were dissolved in dichloromethane (100mL) and cooled to 0 ℃. To the above solution were added 1-hydroxybenzotriazole (2.36g, 17.5mmol), carbodiimide (3.34g, 17.5mmol) and triethylamine (3.21g, 31.8 mmol).
The reaction was stirred at 0-15 ℃ for 6h, then quenched with aqueous hydrochloric acid (20mL,1M) and extracted with dichloromethane (100 mL. times.2). The organic phases were combined and washed with saturated aqueous sodium chloride (50 mL). Separating, collecting organic phase, drying, and concentrating. The residue was subjected to silica gel column chromatography to give compound 6(8.5g) in 93% yield.
Step four: synthesis of Compound 13
Compound 6(1.2g, 2.08mmol) was dissolved in dichloromethane (10mL), cooled to 0 deg.C, and TFA (4mL) was added dropwise thereto. The reaction solution was gradually warmed to room temperature and stirred for 2 h. The solvent and a large amount of trifluoroacetic acid were removed by concentration under reduced pressure, and then ethyl acetate and saturated aqueous sodium carbonate solution were added to Ph 8-9. Extracted with ethyl acetate (50 mL. times.2). The organic phases were combined and washed with saturated aqueous sodium chloride (50 mL). The organic phase was collected by liquid separation, dried and concentrated to obtain compound 13(1.27g) as a white foamy solid with a yield of 98%.
II, synthesizing the compound I
Compound I is prepared according to the process of the present invention, combining the following synthetic routes, in particular as follows:
1. synthesis of Compound 8:
compound 7(40g, 0.57mol) and imidazole (43g, 0.63mol) were dissolved in dichloromethane (1L) and stirred for 10 minutes.
Tert-butyldiphenylchlorosilane (150g, 0.55mol) was dissolved in dichloromethane (500L) and then added dropwise to the above solution. The reaction was stirred at ambient temperature for 20 h.
The reaction mixture was concentrated, and separated by silica gel column chromatography to give compound 8(162g) in 96% yield.
2. Synthesis of Compound 11:
compound 9(32.1mL, 0.29mol) was dissolved in dichloromethane (1.5L). To this was added successively compound 10(30g,0.25mol), magnesium sulfate (146g, 1.21mol) and PPTS (6.2g, 0.025 mol).
The mixture was stirred at room temperature for 20h, filtered through celite, and concentrated. The residue was subjected to silica gel column chromatography to give compound 11(42g) in 91% yield.
3. Synthesis of Compound 12:
compound 8(9.8g, 27.9mmol) was dissolved in dry dichloromethane (162mL), to which Cp was added2Zr hydrochloride (7.7g, 29.8mmol), was stirred at room temperature for 10 min.
Cooling the yellow reaction solution to 0 ℃, and slowly adding AlMe into the yellow reaction solution3(14.9mL, 2.0M in toluene, 29.8 mmol). Stirring was then continued for 10 min.
Compound 11 was dissolved in dry dichloromethane (27mL), added to the above solution and reacted for 12h with stirring.
Ice water (10mL) was slowly added to the reaction mixture in ice bath, and an aqueous hydrochloric acid solution (20mL,1M) was added thereto. Stirring and separating the liquid. The aqueous phase was extracted with dichloromethane (100mL) and the organic phases were combined and washed with saturated sodium chloride solution (150 mL). The organic phase was collected, dried and concentrated. The residue was subjected to silica gel column chromatography to give compound 12(8.6g) in 92% yield.
4. Compound 14 synthesis:
compound 12(20g, 40mmol) was dissolved in 1, 4-dioxane (120mL), cooled to 0 deg.C, and concentrated hydrochloric acid (40mL) was added dropwise with stirring.
The reaction was stirred at room temperature for 16h, extracted with ethyl acetate (200mL × 3). The aqueous phase was retained, 1, 4-dioxane (200mL) was added thereto, stirred for 5min, the reaction was cooled to 0 deg.C and sodium bicarbonate solid (81g, 0.96mol) was added slowly followed by dropwise addition (Boc)2O(10.5g,48mmol)。
The reaction mixture was stirred at room temperature for 8 hours, extracted with ethyl acetate (200 mL. times.3), the organic phases were combined, washed with saturated sodium chloride (200mL), dried and concentrated. The residue was subjected to silica gel column chromatography to give compound 14(9g) in 87% yield.
5. Synthesis of Compound 15:
compound 14(3g, 11.8mmol) was dissolved in acetone (150mL), cooled to 0 deg.C, and stirred.
To the above solution was added Jones reagent (11.8mL, 2.5M), and the reaction was stirred under ice-bath conditions for 2 h.
To the reaction mixture was added isopropanol (5mL), stirred for 5min, and filtered. To the resulting filtrate were added water (50mL) and ethyl acetate (300 mL). Stirring and separating the liquid. The organic phase was washed with saturated sodium chloride (100 mL). Separating, collecting organic phase, drying, and concentrating. The residue was subjected to silica gel column chromatography to give compound 15(3g) in 94% yield.
6. Synthesis of Compound 17:
compound 15(2.6g, 9.6mmol) was dissolved in dry tetrahydrofuran (50mL) and cooled to-78 ℃. To the above solution was added triethylamine (1.46mL, 10.4mmol) and PivCl (1.25mL, 10 mmol). The reaction solution was stirred at-78 deg.C for 20min, warmed to room temperature and stirred for 30 min. The reaction was then cooled to-78 ℃ again.
In another reaction flask, compound 16(1.99g, 11mmol) was dissolved in dry tetrahydrofuran (50mL), cooled to-78 deg.C, and n-butyllithium (4.2mL, 2.5M in tetrahydrofuran) was added dropwise and stirred for 20 min. The lithium salt solution of compound 16 was added dropwise to the above reaction solution containing compound 15, gradually warmed to room temperature, and stirred for 18 hours.
To the reaction mixture were added saturated ammonium chloride (25mL), water (30mL) and ethyl acetate (100 mL). Stirring and separating the liquid. The organic phase was collected and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined and washed with saturated sodium chloride (50 mL). Separating, collecting organic phase, drying, and concentrating. The residue was subjected to silica gel column chromatography to give compound 17(2.6g) in 63% yield.
7. Synthesis of Compound 18:
compound 17(3.3g, 7.67mmol) was dissolved in dry tetrahydrofuran (67mL) and cooled to-78 ℃. NaHMDS (4.22mL, 2M in tetrahydrofuran) was diluted with dry tetrahydrofuran (5mL) and added dropwise to the solution.
After the reaction mixture was stirred at-78 ℃ for 30min, benzyl bromide (13.1g, 76.7mmol) was added thereto. The reaction solution was kept at-45 ℃ and stirred for 12 hours, and the reaction was quenched with saturated ammonium chloride (50mL), followed by extraction with ethyl acetate (100 mL. times.3), and the organic phase was collected and washed with saturated sodium chloride (100 mL). Separating, collecting organic phase, drying, and concentrating. The residue was subjected to silica gel column chromatography to give compound 18(3.3g) in 83% yield.
8. Compound 19 synthesis:
compound 18(1.5g, 2.9mmol) was dissolved in tetrahydrofuran/water (25mL, 4:1 vol), cooled to 0 deg.C, to which was added hydrogen peroxide (1.2mL, 30%), followed by lithium hydroxide monohydrate (480mg, 11.5mmol) and stirred for 1 h.
A saturated solution of sodium thiosulfate (10mL) was added to the reaction mixture, and the pH was adjusted to 5 with saturated sodium dihydrogen phosphate. Extract with ethyl acetate (50mL), collect the organic phase, dry, and concentrate. The residue was subjected to silica gel column chromatography to give compound 19(1g) in 94% yield.
9. Synthesis of Compound 20:
compound 19(0.2g, 0.55mmol) and compound 13(314.0mg, 0.66mmol) were dissolved in dry dichloromethane (5mL) and cooled to 0 ℃. To the above solution were added HATU (274.0mg, 0.72mmol) and DIEA (142.0mg, 1.1 mmol).
The reaction solution was gradually warmed to room temperature, stirred for 3 hours, concentrated to remove the solvent, added with ethyl acetate (30mL) and dilute hydrochloric acid (20mL,1M), stirred and extracted. The organic phase was collected by separation, dried and concentrated to give compound 20(465mg) which was used in the next reaction without further purification.
10. Synthesis of Compound I:
compound 20(465mg, 0.55mmol) was dissolved in tetrahydrofuran/methanol/water (2mL/0.5mL/0.5mL), cooled to 0 deg.C, and a lithium hydroxide solution (1.1mL, 1M aqueous solution) was added dropwise thereto.
The reaction solution was gradually warmed to room temperature with stirring, and stirring was continued for 2 h. The solvent was removed by concentration, the pH was adjusted to 2-3 with aqueous hydrochloric acid (1M), followed by extraction with ethyl acetate (30mL × 2), and the organic phases were combined and washed with saturated aqueous sodium chloride (50 mL). Separating, collecting organic phase, drying, concentrating to obtain crude acid (380mg), and directly using in next condensation reaction.
The crude acid (380mg, 0.55mmol) and 4-amino 2,2,6, 6-tetramethylpiperidine oxide (97mg, 0.57mmol) were dissolved in dry dichloromethane (5mL) and cooled to 0 ℃. To the above solution were added HATU (232mg, 0.61mmol) and DIEA (121mg, 0.94 mmol).
The reaction solution was gradually warmed to room temperature, stirred for 3 hours, concentrated to remove the organic solvent, added with dilute hydrochloric acid (20Ml,1M), extracted with ethyl acetate (30Ml × 2), and the organic phases were combined and washed with saturated aqueous sodium chloride (50 Ml). Separating, collecting organic phase, drying, and concentrating. The residue was subjected to preliminary purification by silica gel column chromatography and then to HPLC preparation to give Compound I (83mg) in 18% yield in three steps.
The target molecular structure contains nitroxide free radicals, and cannot be characterized by conventional nuclear magnetism due to the paramagnetic property of the target molecular structure. The method is characterized in that the ascorbic acid is used for reducing the nitroxide free radicals into the nitroxide free radicals, so that nuclear magnetism characterization is carried out. Mass spectrometry was performed for both molecules simultaneously. The results are as follows:
1H NMR(400MHz,CDCl3)ppm 7.33-7.29(m,6H),7.21-7.15(m,4H),5.63-5.49(m,4H),5.27-5.09(m,4H),4.55-4.46(m,3H),4.15-4.12(m,3H),3.48-3.09(m,8H),2.78-2.75(m,2H),2.30-2.20(m,4H),1.89-1.73(m,5H),1.56-1.49(m,4H),1.42-1.33(m,10H),1.26-1.13(m,12H),0.99-0.95(m,6H),0.87(d,J=6.4Hz,6H)
compound I MS (ESI): 959.6[ M +1 ]]+(ii) a Nitrogen-hydroxyl compound: 960.8[ M +1 ]]+
That is, the compound prepared in this example comprises the following structure:
wherein, the names of the compounds are respectively as follows:
compound 1: (S) -1- (tert-butyloxycarbonyl) pyrolidine-2-carboxylic acid, N-tert-butyloxycarbonyl-L-proline;
compound 2: (S) -tert-butyl2- (((R) -1-methoxy-3-methyl-1-oxobutan-2-yl) carbomoyl) pyrollidine-1-carboxylate, (S) -tert-butyl2- (((R) -1-methoxy-3-methyl-1-oxo-2-butyl) carbamoyl) pyrrolidine-1-carboxylic acid;
compound 3: (R) -2- ((S) -1- (tert-butyloxycarbonyl) pyrolidine-2-carboxamid) -3-methylbutanic acid, (R) -2- ((S) -1- (tert-butyloxycarbonyl) pyrrolidine-2-carboxamido) -3-methylbutanoic acid;
compound 4: (S) -2-amino-5- (((phenyloxy) carbonyl) amino) pentanic acid, (S) -2-amino-5- ((benzyloxycarbonyl) amino) pentanoic acid;
compound 5: (S) -methyl 2-amino-5- (((benzyloxy) carbonyl) amino) pentanate hydrochloride, (S) -2-amino-5- ((benzyloxycarbonyl) amino) pentanoic acid methyl ester hydrochloride;
compound 6: (S) -tert-butyl2- (((R) -1- (((S) -5- (((benzyloxy) carbonyl) amino) -1-methoxy-1-oxopentan-2-yl) amino) -3-methyl-1-oxobutan-2-yl) carbomoyl) pyrollidine-1-carboxylate, (S) -tert-butyl2- (((R) -1- (((S) -5- (((benzyloxy) carbonyl) amino) -1-methoxy-1-oxo-2-pentyl) amino) -3-methyl-1-oxo-2-butyl) carbamoyl) pyrrolidine-1-carboxylic acid;
compound 7: but-3-yn-1-ol, 3-alkyne-1-butanol;
compound 8: (but-3-yn-1-yloxy) (tert-butyl) diphenylsilane, (3-yne-1-butyloxy) tert-butyldiphenylsilyl ether;
compound 9: 3-methylbutanal, 3-methylbutanal;
compound 10: (R) -2-methylpropionamide-2-sulfinamide, (R) -tert-butyl sulfenamide;
compound 11: (R, E) -2-methyl-N- (3-methybutylidene) propane-2-sulfinamide, (R) - ((E) -isoamylimine) -tert-butyl sulfenamide;
compound 12: (R) -N- ((S, E) -8- ((tert-butyldiphenylsilylyl) oxy) -2-methyl-5-en-4-yl) -2-methylpropane-2-sulfenamide, 8-tert-butyldiphenyloxy-2-methyl-5-octene- (S) -4-aza- (R) -tert-butylsulfinamide;
compound 13: (S) -methyl 5- (((benzylioxy) carbonyl) amino) -2- ((R) -3-methyl-2- ((S) -pyrolidine-2-carboxamido) butanamido) pentanoate, (S) -5- ((benzyloxycarbonyl) amino) -2- ((R) -3-methyl-2 ((S) -pyrrolidine-2-carboxamido) -butyrylamino) pentanoic acid methyl ester;
compound 14: (S, E) -tert-butyl (8-hydroxy-2-methyl-5-en-4-yl) carbamate, (S, E) -tert-butyl- (8-hydroxy-2-methyl-5-octene) carbamate;
compound 15: (S, E) -5- ((tert-butylcarbonyl) amino) -7-methyl-3-enoic acid, (S, E) -5- ((tert-butylcarbonyl) amino) -7-methyl-3-octenoic acid;
compound 16: (S) -4-benzyloxyzolidin-2-one, (S) -4-benzyl-3-oxazolidinone;
compound 17: tert-butyl ((S, E) -8- ((S) -4-benzyl-2-oxozolidin-3-yl) -2-methyl-8-oxo-5-en-4-yl) carbamate, tert-butyl ((S, E) -8- ((S) -4-benzyl-2-oxazolidinone) -2-methyl-8-carbonyl-5-alkenyl) -carbamate;
compound 18: tert-butyl ((4S,7S, E) -7-benzyl-8- ((S) -4-benzyl-2-oxoazolidin-3-yl) -2-methyl-8-oxooct-5-en-4-yl) carbamate, tert-butyl ((4S,7S, E) -7-benzyl-8- ((S) -4-benzyl-oxazolidinone) -2-methyl-8-carbonyl-5-enyl) -carbamate;
compound 19: (2S,5S, E) -2-benzyl-5- ((tert-butoxycarbonyl) amino) -7-methyl-3-enoic acid, (2S,5S, E) -2-benzyl-5- ((tert-butoxycarbonyl) amino) -7-methyl-3-octenoic acid;
compound 20: (S) -methyl 2- ((R) -2- ((S) -1- ((2S,5S, E) -2-benzyl-5- ((tert-butylcarbonyl) amino) -7-methyl-3-enyl) pyrolidine-2-carboxamido) -3-methylbutanamido) -5- (((phenyloxy) carbonyl) amino) pentanate, (S) -2- ((R) -2- ((S) -1- (2S,5S, E) -methyl 2-benzyl-5- ((tert-butoxycarbonyl) amino) -7-methyl-3-octene) pyrrolidinyl-2-carboxamido) -3-methylbutanamido) -5- ((benzyloxycarbonyl) amino) pentanoate.
Example 2 measurement of physical and chemical Properties
1. Investigation of pH stability
Buffers with pH 1.2 and pH 8.0 were prepared, as follows:
pH 1.2 hydrochloric acid solution: 765ul concentrated hydrochloric acid is taken in a volumetric flask and diluted to 100ml, thus obtaining the product.
pH 8.0 phosphate buffer solution: 0.2mol/L potassium dihydrogen phosphate solution (solution A): 2.722g of monopotassium phosphate is taken, dissolved in water and diluted to 100 ml; 0.2mol/L sodium hydroxide solution (solution B): taking 800mg of sodium hydroxide, adding water for dissolving, and diluting to 100 ml; and taking 25ml of the solution A and 23.05ml of the solution B, and adding water to dilute to 100ml to obtain the compound.
The incubation was designed and performed as follows:
preparation of compound I stock solution: 1g of the compound I obtained in example 1 are dissolved in a volumetric flask and acetonitrile is added to 10ml to give a standard solution having a concentration of 100 mg/ml.
Then, 10.0. mu.L of compound I stock solution was added to 10mL of the buffer solution at 37 ℃ for 3min of pre-incubation to give a final concentration of 100. mu.g/mL. After reactions t ═ 0, 1,4 and 20 hours, 300. mu.L were sampled and tested on the machine. The content is detected by adopting an LC-MS standard curve method.
Relevant receipts are collected at different time points, and the result shows that the chromatographic peak area and the retention time of the compound I have no obvious change. The results show that compound I prepared in example 1 has good stability in buffers of different pH (see fig. 1-2).
As shown in FIGS. 1-2, the stability of Compound I at pH 8.0 and 1.2 was relatively stable under both acidic and basic conditions for 4 hours; after 20 hours, however, there was partial decomposition of compound I under acidic conditions.
2. Solubility test in buffer
10mg of the solid of Compound I (obtained as described in example 1) are added to 10ml of buffer solution, supersaturated and screwed on, and stirred at 37 ℃ for 24 h. Standing, taking supernatant, filtering, and testing on a machine. The content was measured by LC-MS standard curve method and compared with the standard curve to calculate the solubility in each pH buffer. At pH 7.4, the solubility of compound I was 0.6 mg/mL.
The result shows that compared with the compound XJB-5-131, the solubility of the compound I is greatly improved, and the compound I is beneficial to drug absorption.
EXAMPLE 3 Compound I has inhibitory effect on Erastin-induced apoptosis of HT1080 cells (Ferroptosis)
After the diluted cells are added into a 96-well plate for adherent growth, 10 mu of MERASTIN is added to induce the iron apoptosis (Ferroptosis) state of HT1080 cells, then compound I under different concentrations is added, after incubation is carried out for 24h in 6-well of each concentration, the cell viability is detected by using a CTG (CellTiter-Glo) method, and the half maximum effective concentration of the compound I is obtained and is EC 50-275.2 nM.
The experimental results show that: the inhibition effect of the compound I on Erastin induced HT1080 cell induced iron death shows that the compound I targets mitochondria and can eliminate free radicals generated in cells (see figure 3).
Example 4 Hydrogen peroxide Induction of ARPE cell death
The diluted cells were added to 96-well plates and after adherent growth, different concentrations of H2O2 (300. mu. mol/L) were added to normal groups and 6 wells per concentration. After adherent growth, drugs (1 × 10-1 × 10-5mol/L) with different concentrations are added, each concentration is 6 holes, and the control group is added with DMSO and culture solution mixed liquor (without drugs) with the same volume. Adding H2O2 (concentration of about 30% and 50% proliferation inhibition rate), incubating at 37 deg.C for a certain time, adding MTT solution, incubating for 4H/37 deg.C, pouring out most culture solution, adding 100mL DMSO to dissolve purple crystal, and reading with enzyme-labeling instrument to obtain OD value.
The experimental results show that: the compound I has a recovery effect on ARPE-19 cells damaged by hydrogen peroxide (see figure 4). As shown in FIG. 4, under the induction of 300. mu. mol/L hydrogen peroxide, the compound I has the effect of restoring ARPE-19 cells.
Example 5 Dry age-related macular degeneration (Dry-AMD) detection
After the quarantine of 24 SD rats is finished, visual electrophysiological detection is carried out and the FERG is recorded. Animals were randomized into three groups (n ═ 8), normal group, model group, compound I treatment group (group I, administered with compound I prepared in example 1) according to the FERG b wave amplitude. Model group and treatment group, wherein the model is made by illuminating for 8h in a 10000Lux white cold light source illumination box, and after the illumination is finished, the animal is transferred to an experimental animal room for normal feeding. After successful modeling, the normal group and the model group were each administered intravitreally with a blank physiological saline, and the compound I treatment group (group I, administered with compound I prepared in example 1) was each administered intravitreally with 0.1 mg/kg. The time was continuously observed for two cycles by the FERG wave amplitude, and the a-wave and b-wave amplitudes were recorded. Two weeks later, the animals were sacrificed and then the animals were sampled and HE stained sections were taken to observe retinal thickness changes and the like.
The results show that: at a concentration of 0.05mM, the b-wave amplitude change value of compound I was significantly different from that of the model group (see fig. 5). As shown in fig. 5, the SD rats had significant difference in b-wave at 0.05mM under white light illumination for 8h, indicating that compound I can protect retinal cell apoptosis.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
While embodiments of the invention have been shown and described, it will be understood by those of ordinary skill in the art that: various changes, modifications, substitutions and alterations can be made to the embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the claims and their equivalents.
Claims (6)
1. A compound of formula I or a stereoisomer, geometric isomer, tautomer, nitroxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt of a compound of formula I,
wherein,
cbz represents benzyloxycarbonyl, Bn represents benzyl, and Boc represents t-butoxycarbonyl.
2. A process for preparing a compound of claim 1, comprising the steps of:
contacting 3-yne-1-butanol with imidazole and tert-butyldiphenylchlorosilane so as to obtain (3-yne-1-butyloxy) tert-butyldiphenylsilyl ether;
contacting 3-methylbutanal with (R) -tert-butylsulfenamide, magnesium sulfate and PPTS, so as to obtain (R) - ((E) -isoamylimine) -tert-butylsulfenamide;
contacting (3-yne-1-butyloxy) tert-butyldiphenylsilyl ether with (R) - ((E) -isoamylimine) -tert-butylsulfinamide, so as to obtain 8-tert-butyldiphenylsiloxy-2-methyl-5-octene- (S) -4-aza- (R) -tert-butylsulfinamide;
contacting 8-tert-butyldiphenylsiloxy-2-methyl-5-octene- (S) -4-aza- (R) -tert-butylsulfinamide with a solid sodium bicarbonate to obtain (S, E) -tert-butyl- (8-hydroxy-2-methyl-5-octene) carbamate;
contacting (S, E) -tert-butyl- (8-hydroxy-2-methyl-5-octene) carbamate with jones reagent to obtain (S, E) -5- ((tert-butylcarbonyl) amino) -7-methyl-3 octenoic acid;
contacting (S, E) -5- ((tert-butylcarbonyl) amino) -7-methyl-3 octenoic acid with (S) -4-benzyl-3-oxazolidinone to obtain tert-butyl ((S, E) -8- ((S) -4-benzyl-2-oxazolidinone) -2-methyl-8-carbonyl-5-enyl) -carbamate;
contacting tert-butyl ((S, E) -8- ((S) -4-benzyl-2-oxazolidinone) -2-methyl-8-carbonyl-5-enyl) -carbamate with tetrahydrofuran and benzyl bromide to obtain tert-butyl ((4S,7S, E) -7-benzyl-8- ((S) -4-benzyl-oxazolidinone) -2-methyl-8-carbonyl-5-enyl) -carbamate;
contacting tert-butyl ((4S,7S, E) -7-benzyl-8- ((S) -4-benzyl-oxazolidinone) -2-methyl-8-carbonyl-5-enyl) -carbamate with hydrogen peroxide, lithium hydroxide monohydrate, and sodium thiosulfate to obtain (2S,5S, E) -2-benzyl-5- ((tert-butoxycarbonyl) amino) -7-methyl-3-octenoic acid;
contacting (2S,5S, E) -2-benzyl-5- ((tert-butoxycarbonyl) amino) -7-methyl-3-octenoic acid with (S) -5- ((benzyloxycarbonyl) amino) -2- ((R) -3-methyl-2 ((S) -pyrrolidine-2-carboxamido) -butyrylamino) pentanoic acid methyl ester, so as to obtain (S) -methyl 2- ((R) -2- ((S) -1- (2S,5S, E) -2-benzyl-5- ((tert-butoxycarbonyl) amino) -7-methyl-3-octene) pyrrolidinyl-2-carboxamido) -3-methylbutanamido) -5- ((benzyloxycarbonyl) amino) pentanoate; and
contacting methyl (S) -2- ((R) -2- ((S) -1- (2S,5S, E) -2-benzyl-5- ((tert-butoxycarbonyl) amino) -7-methyl-3-octene) pyrrolidinyl-2-carboxamido) -3-methylbutanamido) -5- ((benzyloxycarbonyl) amino) pentanoate with sodium hydroxide to give a crude product, which is then contacted with 4-amino 2,2,6, 6-tetramethylpiperidine oxide, 1-hydroxybenzotriazole, carbodiimide and 4-dimethylaminopyridine to obtain the compound of claim 1.
3. A pharmaceutical composition comprising a compound of claim 1.
4. The pharmaceutical composition of claim 3, further comprising a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle, or any combination thereof.
5. Use of the compound of claim 1 or the pharmaceutical composition of claim 3 or 4 for the preparation of a medicament for the prevention or treatment of a neurodegenerative disease.
6. Use according to claim 5, wherein said neurodegenerative disease comprises dry senile maculopathy, glaucoma, traumatic brain injury, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510922167 | 2015-12-11 | ||
CN2015109221678 | 2015-12-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106866784A true CN106866784A (en) | 2017-06-20 |
CN106866784B CN106866784B (en) | 2021-05-18 |
Family
ID=59163885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611130474.3A Active CN106866784B (en) | 2015-12-11 | 2016-12-09 | Targeted mitochondrial antioxidant and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106866784B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019041361A1 (en) * | 2017-09-04 | 2019-03-07 | Xw Laboratories, Inc. | Preparation and use of reactive oxygen species scavenger |
US10858394B2 (en) | 2017-08-17 | 2020-12-08 | Xw Laboratories Inc. | Preparation and uses of reactive oxygen species scavenger derivatives |
CN113804789A (en) * | 2021-09-18 | 2021-12-17 | 湖北石河医药科技有限公司 | Separation and detection method of compound A with multiple chiral sites and chiral isomer thereof and application of compound A in synthesis process |
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
CN114984180A (en) * | 2022-07-21 | 2022-09-02 | 南京鼓楼医院 | Application of XJB-5-131 in preparation of osteoarthritis treatment drug |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
CN115814087A (en) * | 2022-09-26 | 2023-03-21 | 蔡菁菁 | Application of mitochondrial oxidized cardiolipin as target in screening products for preventing and treating endotoxemia-related cardiac dysfunction |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY37341A (en) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070161573A1 (en) * | 2006-01-06 | 2007-07-12 | Peter Wipf | Selective targeting agents for mitochondria |
WO2010009327A1 (en) * | 2008-07-17 | 2010-01-21 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compounds for the treatment of pathologies associated with aging and degenerative disorders |
WO2010141824A2 (en) * | 2009-06-05 | 2010-12-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Use of targeted nitroxide agents in bone healing |
WO2012068081A1 (en) * | 2010-11-15 | 2012-05-24 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Intraesophageal administration of targeted nitroxide agents for protection against ionizing irradiation-induced esophagatis |
US20150297578A1 (en) * | 2006-01-06 | 2015-10-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Selective Targeting Agents for Mitochondria |
CN111356699A (en) * | 2017-09-04 | 2020-06-30 | 凯瑞康宁生物工程(武汉)有限公司 | Preparation and use of active oxygen scavenger |
-
2016
- 2016-12-09 CN CN201611130474.3A patent/CN106866784B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070161573A1 (en) * | 2006-01-06 | 2007-07-12 | Peter Wipf | Selective targeting agents for mitochondria |
US20150297578A1 (en) * | 2006-01-06 | 2015-10-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Selective Targeting Agents for Mitochondria |
WO2010009327A1 (en) * | 2008-07-17 | 2010-01-21 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compounds for the treatment of pathologies associated with aging and degenerative disorders |
WO2010141824A2 (en) * | 2009-06-05 | 2010-12-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Use of targeted nitroxide agents in bone healing |
WO2012068081A1 (en) * | 2010-11-15 | 2012-05-24 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Intraesophageal administration of targeted nitroxide agents for protection against ionizing irradiation-induced esophagatis |
CN111356699A (en) * | 2017-09-04 | 2020-06-30 | 凯瑞康宁生物工程(武汉)有限公司 | Preparation and use of active oxygen scavenger |
Non-Patent Citations (4)
Title |
---|
JIANG JI等: "Global lipidomics identifies cardiolipin oxidation as a mitochondrial target for redox therapy of acute brain injury", 《NAT NEUROSCI》 * |
KRAINZ,TANJA等: "A Mitochondrial-targeted Nitroxide Is a Potent Inhibitor of Ferroptosis", 《ACS CENTRAL SCIEVSE》 * |
PETER WIPF等: "Mitochondrial Targeting of Selective Electron Scavengers: Synthesis and Biological Analysis of hemigramicidin-TEMPO Conjugates", 《J.AM.CHEM.SOC》 * |
ZHIYIN XUN等: "Targeting of XJB-5-131 to Mitochondria Suppresses Oxidative DNA Damage and Motor Decline in a Mouse Model of Huntington’s Disease", 《CELL REPORTS》 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11766418B2 (en) | 2016-07-22 | 2023-09-26 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US10858394B2 (en) | 2017-08-17 | 2020-12-08 | Xw Laboratories Inc. | Preparation and uses of reactive oxygen species scavenger derivatives |
US11692008B2 (en) | 2017-08-17 | 2023-07-04 | XWPharma Ltd. | Preparation and uses of reactive oxygen species scavenger derivatives |
US11312703B2 (en) | 2017-09-04 | 2022-04-26 | XWPharma Ltd. | Reactive oxygen species scavengers and use for treating diseases |
WO2019041361A1 (en) * | 2017-09-04 | 2019-03-07 | Xw Laboratories, Inc. | Preparation and use of reactive oxygen species scavenger |
US10889572B2 (en) | 2017-09-04 | 2021-01-12 | Xw Laboratories Inc. | Reactive oxygen species scavengers and use for treating diseases |
JP2020532554A (en) * | 2017-09-04 | 2020-11-12 | エックスダブリュー ラボラトリーズ,インコーポレイテッド | Preparation and use of reactive oxygen species scavengers |
CN111356699A (en) * | 2017-09-04 | 2020-06-30 | 凯瑞康宁生物工程(武汉)有限公司 | Preparation and use of active oxygen scavenger |
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
CN113804789A (en) * | 2021-09-18 | 2021-12-17 | 湖北石河医药科技有限公司 | Separation and detection method of compound A with multiple chiral sites and chiral isomer thereof and application of compound A in synthesis process |
CN113804789B (en) * | 2021-09-18 | 2023-04-18 | 湖北石河医药科技有限公司 | Separation and detection method of compound A with multiple chiral sites and chiral isomer thereof and application of compound A in synthesis process |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
CN114984180B (en) * | 2022-07-21 | 2023-08-01 | 南京鼓楼医院 | Application of XJB-5-131 in preparation of medicine for treating osteoarthritis |
CN114984180A (en) * | 2022-07-21 | 2022-09-02 | 南京鼓楼医院 | Application of XJB-5-131 in preparation of osteoarthritis treatment drug |
CN115814087A (en) * | 2022-09-26 | 2023-03-21 | 蔡菁菁 | Application of mitochondrial oxidized cardiolipin as target in screening products for preventing and treating endotoxemia-related cardiac dysfunction |
CN115814087B (en) * | 2022-09-26 | 2024-04-16 | 蔡菁菁 | Application of mitochondrial oxidized cardiolipin as target in screening product for preventing and treating endotoxemia-related cardiac dysfunction |
Also Published As
Publication number | Publication date |
---|---|
CN106866784B (en) | 2021-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106866784B (en) | Targeted mitochondrial antioxidant and preparation method and application thereof | |
KR100655808B1 (en) | Colchinol derivatives as vascular damaging agents, their use and method for preparation thereof | |
CA2978458C (en) | Glucosylceramide synthase inhibitors for the treatment of diseases | |
MX2014014563A (en) | Solid forms of an antiviral compound. | |
JP4954864B2 (en) | Prodrugs of ion channel modulating compounds and uses thereof | |
EA023223B1 (en) | PYRAZOLO[1,5-a]PYRIMIDINES FOR ANTIVIRAL TREATMENT | |
CN101346370A (en) | PDF inhibitors | |
US20210363165A1 (en) | Nitroxoline prodrug and use thereof | |
AU2012258665B2 (en) | Quinone compounds for treating Ape1 mediated diseases | |
JP2011514364A (en) | Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain | |
CN104854093B (en) | New SARM | |
CN102234287A (en) | Nitro imidazole compound, its preparation method and application | |
TW200407310A (en) | Compounds | |
JP7152078B2 (en) | Borate-based drugs and their uses | |
EP2767533B1 (en) | Derivative of butylphthalide and preparation method and use thereof | |
CN110590839B (en) | Levatinib derivative and preparation method and application thereof | |
CN114149395B (en) | Benzocyclopentenone derivative, preparation method and medical application thereof | |
EA030709B1 (en) | Phenanthroline phosphonic acid derivative and preparation method therefor and application thereof | |
WO2020172565A1 (en) | Methods and materials for increasing or maintaining nicotinamide mononucleotide adenylyl transferase-2 (nmnat2) polypeptide levels | |
CN113698383B (en) | Piperazine compound and application thereof | |
EP2570408B1 (en) | Hexaketide compound and medicinal use thereof | |
RU2322438C2 (en) | Azaspiro-compounds for pain treatment | |
CN116836216A (en) | Fulvestrant derivative, preparation method and medical application thereof | |
CA3222586A1 (en) | Inhibitors of ttbk1 | |
EP4406962A1 (en) | Macrocyclic peptidomimetic protease inhibitor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |